INTRODUCTION {#s1}
============

Smoking in pregnancy is a significant public health problem. In the United Kingdom, a country with strong tobacco control culture, a survey in 2011 found that 26% of pregnant women smoked at some point before or during pregnancy and 12% smoked constantly throughout gestation ([@CIT0006]). As smoking is a completely preventable cause of poor health outcomes for mothers and their babies, stopping smoking before or during pregnancy is vital. Unfortunately, though, there are few evidence-based cessation interventions that are proven to work for cessation in pregnancy.

A systematic review investigating the predictors of quit attempts made by nonpregnant smokers, found that a lower number of previous quit attempts and higher levels of nicotine dependence were both inversely associated with cessation ([@CIT0016]). Factors that have been associated with increased number of quit attempts in pregnancy also include age and smoking duration ([@CIT0017]). However, a recent systematic review found that having a partner who smoked, multiparity and increasing nicotine dependence had, in many studies, been found inversely associated with likelihood of achieving cessation ([@CIT0012]). Additionally, socioeconomic factors such as increased income and educational levels of the mother and partner have also been shown to be associated with cessation in pregnancy ([@CIT0007]; [@CIT0010]; [@CIT0012]), but these associations may be due to decline in smoking rates, which has been found to be lower in women from lower socioeconomic groups ([@CIT0015]). Data from surveys conducted in the United Kingdom and Spain have also found that pregnant women with lower educational and socioeconomic levels have lower chances of cessation, whereas women who smoked fewer cigarettes, started smoking at an older age, had a partner who did not smoke or were primiparous were more likely to quit ([@CIT0014]).

There is less evidence, though, about which factors might influence women's success when using nicotine replacement therapy (NRT) in cessation attempts made during pregnancy. Although nicotine dependence appears central to maintaining smoking behavior in pregnancy, attempts to promote cessation in pregnancy by addressing this with NRT have thus far been unsuccessful ([@CIT0001]). Further investigation of factors associated with cessation in pregnancy is warranted and analyses using data from studies in which an attempt has been made to treat nicotine dependence would be particularly informative. Recently, the Smoking, Nicotine, and Pregnancy (SNAP) trial, a large trial investigating the use of NRT for smoking cessation in pregnancy was conducted ([@CIT0002]), and using the cohort of participants from this trial, we investigate independent associations between participants' baseline characteristics and cessation at both early and late follow-up points to help ascertain whether or not any might be potential determinants of successful cessation.

METHODS {#s2}
=======

Data Source {#s3}
-----------

Data for explanatory variables in these analyses were collected at baseline and outcome variable data were collected at two subsequent follow-up points within the SNAP trial ([@CIT0002]). Trial participants were aged 16--45 years; of 12--24 weeks gestation; smoked ≥10 cigarettes prior to pregnancy and smoked ≥5 cigarettes currently; and had exhaled carbon monoxide (CO) readings of \>8 parts per million (ppm).

Treatment Protocol {#s4}
------------------

Between May 2007 and February 2010, 1,050 participants were recruited to the trial from seven English hospital antenatal clinics. Research midwives collected baseline data, prescribed trial patches and provided face-to-face behavioral support at enrollment, and collected follow-up data at contacts; 1 month and delivery. Women received a behavioral support session lasting up to 1hr at enrollment. A quit date was also set within 2 weeks of enrollment and the follow-up points were measured from this. Women were offered additional behavioral support from the local National Health Service (NHS) stop smoking services throughout the trial to all participants according to the national standards, and research midwives provided telephone support when women were contacted on their quit date, 3 days after this and at 1 month. Participants were randomized to receive either NRT (15mg/16hr) or identical placebo patches. The first 4 weeks supply of patches was issued on the quit date, with a second batch of 4 weeks of patches given to those women reported not smoking and who had CO validation at the 1-month follow-up. Full methods ([@CIT0002]) including the initial ([@CIT0003]) and final ([@CIT0004]) protocols for this study are published elsewhere.

Baseline Data: Explanatory Variables {#s5}
------------------------------------

Prior to randomization, the following data were collected from participants: date of birth, ethnicity, age on completion of full time education, partner's smoking status, parity, gestational age, body mass index, and previous use of NRT during their current pregnancy. Saliva and blood samples were taken for cotinine estimation, along with exhaled CO readings to estimate smoke and nicotine intake, respectively. Trial recruitment site and participants' treatment assignment (i.e., NRT or placebo) were also available from the trial database.

Outcome Variables {#s6}
-----------------

For analyses in this paper, we used validated cessation at 1-month postquit date and at delivery as outcome variables. At 1 month, cessation was defined as continuous abstinence from quit date to 1 month, validated by an exhaled CO reading of ≤8 ppm; and, at delivery, cessation was defined as continuous abstinence from a quit date until delivery, validated by an exhaled CO reading of ≤8 ppm and/or a saliva cotinine level of \<10ng/ml. Participants who were lost to follow-up were coded as continuing smokers.

Analysis Strategy {#s7}
-----------------

This analysis investigated associations between baseline characteristics of participants and cessation at 1 month after initiating treatment (i.e., from quit date) and at delivery. Two multivariable logistic models were built. Initially, for both models, variables were identified which had significant univariate associations (*p* ≤ .05) with validated cessation at each timepoint. Secondly, these variables were all entered into a multivariable model using stepwise backwards elimination to remove variables found to have nonsignificant associations with outcome (*p* \> .05). Finally, variables which showed no association at the univariate level were entered into the models individually, to determine if they were subsequently associated with validated cessation. Treatment assignment was included as an *a-priori* confounder.

To maximize the number of participants included in the analysis, where possible, a missing category was created for categorical variables with missing data and imputation was planned for continuous variables (baseline cotinine) where \>10% of cases had missing data. Where all missing values for an exposure occurred among people in the same outcome category (i.e., continuing smokers) or a small percentage of data was missing for a continuous variable, a univariate sensitivity analysis comparing all participants against those with complete data was conducted, to verify that they did not differ in their baseline characteristics.

All analyses were conducted using Stata 11.2 (College Station, TX).

RESULTS {#s8}
=======

In the 1 month and delivery multivariate analyses, missing data for the categorical variable "age full time education finished" could not be included as all those with missing data were smokers at follow-up and inclusion as an extra category would perfectly predict the outcome. Furthermore, imputation for the continuous variable "baseline cotinine level" was not carried out due to data being missing for only 80 participants (7.6%). As a result, analysis was undertaken on 957/1,050 participants (91.1%), for whom complete exposure data were available. Including the 93 participants for whom some baseline data were missing in the final multivariable model, did not alter the results. An analysis based on achieving validated cessation was conducted and characteristics of the women included are detailed in [Table 1](#T1){ref-type="table"}. At 1 month 167 (17.5%), and at delivery 84 (8.8%) of the participants achieved validated cessation.

###### 

Participant Characteristics for Cessation at 1 Month and Delivery

  Variable                                              One month          Delivery                             
  ----------------------------------------------------- ------------------ ----------------- ------------------ ------------------
  Age (median \[IQR\]) (years)                          25 (21--30)        25 (21--31)       25 (21--30)        25 (21--31)
  Primiparous                                           36.8%              37.1%             36.3%              42.9%
  Age full-time education finished (years)                                                                      
      ≤16                                               80.5%              68.9%             79.6%              66.7%
      \>16                                              19.5%              31.1%             20.4%              33.3%
  Ethnicity                                                                                                     
      British: White                                    97.3%              96.4%             97.4%              95.2%
      Other                                             2.7%               3.6%              2.6%               4.8%
  Gestational age (median \[IQR\]) (weeks)              15 (13--18)        15 (13--18)       15 (13--18)        15 (13--20)
  Baseline cotinine (median \[IQR\]) (ng × 10^−1^/ml)   12.7 (8.7--18.2)   9.1 (5.8--13.8)   12.4 (8.1--17.8)   10.6 (6.0--15.3)

*Note.* IQR = interquartile range.

Factors Associated With Smoking Cessation at 1 Month {#s9}
----------------------------------------------------

At 1 month, in the univariate analysis, women who finished full time education when they were \>16 years had greater odds of cessation; women who had a higher baseline cotinine levels, and those who were recruited from trial site 4, were found to have lower odds of cessation ([Table 2](#T2){ref-type="table"}). The final multivariable model shows which baseline variables were independently associated with validated cessation at 1 month. Women who were aged \>16 years when they finished full time education (odds ratio \[*OR*\] = 1.82, 95% confidence interval \[CI\] = 1.24--2.67, *p* = .002) had significantly increased odds of achieving validated cessation. Participants who had a higher baseline cotinine (*OR* = 0.94, 95% CI = 0.91--0.96, *p* \< .001 for a 10ng/ml increase) had significantly lower odds of cessation at 1 month after quit date. The effect of trial recruitment site 4 did not remain significant when added to the multivariable model (*OR* = 0.69, 95% CI = 0.36--1.34, *p* = .277).

###### 

Univariate and Multivariate Associations With Validated Cessation at 1 Month

  Variable                                     *N*   Smoking at 1 month (%)   Cessation at 1 month (%)   Crude *OR*   95% CI   *p* value   Adjusted *OR*   95% CI   LRT *p* value          
  -------------------------------------------- ----- ------------------------ -------------------------- ------------ -------- ----------- --------------- -------- --------------- ------ ---------
  Age (years)^†^                                                                                                                                                                           
      \<20                                     147   129 (87.8)               18 (12.2)                  0.64         0.36     1.12        0.250\*         --       --              --     --
      20--24                                   322   264 (82.0)               58 (18.0)                  1.00         --       --          --              --       --                     
      25--29                                   228   183 (80.3)               45 (19.7)                  1.12         0.73     1.73        --              --       --                     
      30--34                                   158   134 (84.8)               24 (15.2)                  0.82         0.49     1.37        --              --       --                     
      35--39                                   78    63 (80.8)                15 (19.2)                  1.08         0.58     2.04        --              --       --                     
      ≥40                                      24    17 (70.8)                7 (29.2)                   1.87         0.74     4.73        --              --       --                     
  Ethnicity                                                                                                                                                                                
      Other                                    27    21 (77.8)                6 (22.2)                   1.00         --       --          0.521           --       --              --     --
      British: White                           930   769 (82.7)               161 (17.3)                 0.73         0.29     1.84        --              --       --                     
  Age full time education finished                                                                                                                                                         
      ≤16                                      751   636 (84.7)               115 (15.3)                 1.00         --       --          0.001           1.00     --              --     0.002
      \>16                                     206   154 (74.8)               52 (25.2)                  1.87         1.29     2.71        1.82            1.24     2.67                   
  Partner smokes                                                                                                                                                                           
      No                                       225   186 (82.7)               39 (17.3)                  1.00         --       --          0.412           --       --              --     --
      Yes                                      654   544 (83.2)               110 (16.8)                 0.96         0.65     1.44        --              --       --                     
      Not applicable                           78    60 (76.9)                18 (23.1)                  1.43         0.76     2.69        --              --       --                     
  Parity                                                                                                                                                                                   
      ≤1                                       649   535 (82.4)               114 (17.6)                 1.00         --       --          0.919\*         --       --              --     
      2 or 3                                   256   211 (82.4)               45 (17.6)                  1.00         0.68     1.46        --              --       --                     
      ≥4                                       52    44 (84.6)                8 (15.4)                   0.85         0.39     1.86        --              --       \-                     
  Baseline cotinine (ng × 10^−1^/ml)                                                                                                                                                       
  12.1 (7.8--17.6), median (IQR)               957   790 (82.6)               167 (17.4)                 0.93         0.90     0.95        \<0.001         0.93     0.90            0.95   \<0.001
  BMI                                                                                                                                                                                      
      \<18.5                                   28    27 (96.4)                1 (3.6)                    0.18         0.02     1.34        0.987\*         --       --              --     --
      18.5--24.9                               362   300 (82.9)               62 (17.1)                  1.00         --       --          --              --       --                     
      25--29.9                                 267   213 (79.8)               54 (20.2)                  1.23         0.82     1.84        --              --       --                     
      \>30                                     254   212 (83.5)               42 (16.5)                  0.96         0.62     1.47        --              --       --                     
      Missing                                  46    38 (82.6)                8 (17.4)                   1.02         0.45     2.29        --              --       --                     
  Length of first behavioral support session                                                                                                                                               
      16--30                                   143   123 (86.0)               20 (14.0)                  1.00         --       --          0.478           --       --              --     --
      31--45                                   791   648 (81.9)               143 (18.1)                 1.36         0.82     2.25        --              --       --                     
      \>60                                     23    19 (82.6)                4 (17.4)                   1.29         0.40     4.20        --              --       --                     
  Previous preterm births                                                                                                                                                                  
      0                                        872   718 (82.3)               154 (17.7)                 1.00         --       --          0.577           --       --              --     --
      ≥1                                       85    72 (84.7)                13 (15.3)                  0.84         0.45     1.56        --              --       --                     
  Use of NRT since pregnancy began                                                                                                                                                         
      No                                       914   756 (82.7)               158 (17.3)                 1.00         --       --          0.548           --       --              --     --
      Yes                                      43    34 (79.1)                9 (20.9)                   1.27         0.60     2.69        --              --       --                     
  Trial recruitment site                                                                                                                                                                   
      Site 1                                   102   81 (79.4)                21 (20.6)                  1.00         --       --          0.032           --       --              --     --
      Site 2                                   113   97 (85.8)                16 (14.2)                  0.64         0.31     1.30        --              --       --                     
      Site 3                                   188   151 (80.3)               37 (19.7)                  0.95         0.52     1.72        --              --       --                     
      Site 4                                   238   212 (89.1)               26 (10.9)                  0.47         0.25     0.89        --              --       --                     
      Site 5                                   165   127 (77.0)               38 (23.0)                  1.15         0.63     2.11        --              --       --                     
      Site 6                                   77    63 (81.8)                14 (18.2)                  0.86         0.40     1.82        --              --       --                     
      Site 7                                   74    59 (79.7)                15 (20.3)                  0.98         0.47     2.06        --              --       --                     
  Gestational age (weeks)                                                                                                                                                                  
      12--19                                   766   637 (83.2)               129 (16.8)                 1.00         --       --          0.326           --       --              --     --
      20--24                                   191   153 (80.1)               38 (19.9)                  1.23         0.82     1.83                        --       --              --     

*Note.* BMI = body mass index; CI = confidence interval; IQR = interquartile range; LRT = likelihood ratio test; NRT = nicotine replacement therapy; *OR* = odds ratio.

\**p* value: test for trend.

^†^Age included as continuous variable in multivariate model to derive *p* value, equivalent to test for trend adjusting for covariates.

Factors Associated With Smoking Cessation at Delivery {#s10}
-----------------------------------------------------

[Table 3](#T3){ref-type="table"} shows the univariable and multivariable associations with validated cessation at delivery; the univariable results found women who finished full time education at \>16 years and had lower baseline cotinine levels had increased odds of cessation and those with higher baseline cotinine levels had lower odds of cessation. In the final multivariable model, women who continued school beyond the compulsory minimum age (16 years) were more likely to stop smoking (*OR* = 1.89, 95% CI = 1.16--3.07, *p* = .010) and women with a higher baseline cotinine level were less likely to achieve cessation (*OR* = 0.96, 95% CI = 0.92--0.99, *p* \< .010).

###### 

Univariate and Multivariate Associations With Validated Cessation at Delivery

  Variable                                     *N*   Smoking at delivery (%)   Cessation at delivery (%)   Crude *OR*   95% CI   *p* value   Adjusted *OR*   95% CI   LRT *p* value          
  -------------------------------------------- ----- ------------------------- --------------------------- ------------ -------- ----------- --------------- -------- --------------- ------ -------
  Age                                                                                                                                                                                        
      \<20                                     147   135 (91.8)                12 (8.2)                    0.93         0.46     1.89        0.403\*         --       --              --     --
      20--24                                   322   294 (91.3)                28 (8.7)                    1.00         --       --          --              --       --                     
      25--29                                   228   206 (90.4)                22 (9.7)                    1.12         0.62     2.02        --              --       --                     
      30--34                                   158   145 (91.8)                13 (8.2)                    0.94         0.47     1.87        --              --       --                     
      35--39                                   78    74 (94.9)                 4 (5.1)                     0.57         0.19     1.67        --              --       --                     
      ≥40                                      24    19 (79.2)                 5 (20.8)                    2.76         0.96     7.96        --              --       --                     
  Ethnicity                                                                                                                                                                                  
      Other                                    27    23 (85.2)                 4 (14.8)                    1.00         --       --          0.300           --       --              --     --
      British - White                          930   850 (91.4)                80 (8.6)                    0.54         0.18     1.60        --              --       --                     
  Age full time education finished                                                                                                                                                           
      ≤16                                      751   695 (92.5)                56 (7.5)                    1.00         --       --          0.009           1.00     --              --     0.010
      \>16                                     206   178 (86.4)                28 (13.6)                   1.95         1.20     3.16        1.89            1.16     3.07                   
  Partner smokes                                                                                                                                                                             
      No                                       78    199 (88.4)                26 (11.6)                   1.00         --       --          0.193           --       --              --     --
      Yes                                      225   604 (92.4)                50 (7.6)                    0.63         0.38     1.04        --              --       --                     
      Not applicable                           654   70 (89.7)                 8 (10.3)                    0.87         0.38     2.02        --              --       --                     
  Parity                                                                                                                                                                                     
      ≤1                                       649   588 (90.6)                61 (9.4)                    1.00         --       --          0.304\*         --       --              --     --
      2 or 3                                   256   235 (91.8)                21 (8.2)                    0.86         0.51     1.45        --              --       --                     
      ≥4                                       52    50 (96.2)                 2 (3.8)                     0.39         0.09     1.62        --              --       --                     
  Baseline cotinine (ng × 10^−1^/ml)                                                                                                                                                         
  12.1 (7.8--17.6), median (IQR)               957   873 (91.2)                84 (8.8)                    0.95         0.92     0.98        0.002           0.96     0.92            0.99   0.010
  Length of first behavioral support session                                                                                                                                                 
      16--30                                   143   135 (94.4)                8 (5.6)                     1.00         --       --          0.258           --       --              --     --
      31--45                                   791   718 (90.8)                73 (9.2)                    1.72         0.81     3.64        --              --       --                     
      \>60                                     23    20 (87.0)                 3 (13.0)                    2.53         0.62     10.34       --              --       --                     
  BMI                                                                                                                                                                                        
      \<18.5                                   28    27 (96.4)                 1 (3.6)                     0.44         0.06     3.37        0.273\*         --       --              --     --
      18.5--24.9                               362   334 (92.3)                28 (7.7)                    1.00         --       --          --              --       --                     
      25--29.9                                 267   243 (91.0)                24 (9.0)                    1.18         0.67     2.08        --              --       --                     
      \>30                                     254   225 (88.6)                29 (11.4)                   1.54         0.89     2.65        --              --       --                     
      Missing                                  46    44 (95.7)                 2 (4.3)                     0.54         0.12     2.35        --              --       --                     
  Previous preterm births                                                                                                                                                                    
      0                                        872   795 (91.2)                77 (8.8)                    1.00         --       --          0.852           --       --              --     --
      ≥1                                       85    78 (91.8)                 7 (8.2)                     0.93         0.41     2.08        --              --       --                     
  Use of NRT since pregnancy began                                                                                                                                                           
      No                                       914   837 (91.6)                77 (8.4)                    1.00         --       --          0.106           --       --              --     --
      Yes                                      43    36 (83.7)                 7 (16.3)                    2.11         0.91     4.91        --              --       --                     
  Trial recruitment site                                                                                                                                                                     
      Site 1                                   102   90 (88.2)                 12 (11.8)                   1.00         --       --          0.397           --       --              --     --
      Site 2                                   113   106 (93.8)                7 (6.2)                     0.50         0.19     1.31        --              --       --                     
      Site 3                                   188   172 (91.5)                16 (8.5)                    0.70         0.32     1.54        --              --       --                     
      Site 4                                   238   221 (92.9)                17 (7.1)                    0.58         0.26     1.26        --              --       --                     
      Site 5                                   165   152 (92.1)                13 (7.9)                    0.64         0.28     1.47        --              --       --                     
      Site 6                                   77    69 (89.6)                 8 (10.4)                    0.87         0.34     2.24        --              --       --                     
      Site 7                                   74    63 (85.1)                 11 (14.9)                   1.31         0.54     3.15        --              --       --                     
  Gestational age (weeks)                                                                                                                                                                    
      12--19                                   766   704 (91.9)                62 (8.1)                    1.00         --       --          0.147           --       --              --     --
      20--24                                   191   169 (88.5)                22 (11.5)                   1.48         0.88     2.47                        --       --              --     

*Note.* BMI = body mass index; CI = confidence interval; IQR = interquartile range; LRT = likelihood ratio test; NRT = nicotine replacement therapy; *OR* = odds ratio.

\**p* value: test for trend.

DISCUSSION {#s11}
==========

Main Findings {#s12}
-------------

We found that, among participants in a trial of transdermal nicotine patches in pregnancy, smoking cessation of 1-month duration and also until delivery were positively associated with finishing full time education beyond the compulsory age of 16 years and negatively associated with baseline cotinine levels. Leaving school at 16 years is a marker of social disadvantage and also an indicator of lower socioeconomic status, which is associated with decreased probability of quitting.

Strengths and Limitations {#s13}
-------------------------

The main limitation of this study was that a relatively restricted variety of variables were collected in the trial; in particular, there were few behavioral or socioeconomic measures, which, in some studies have been shown to influence cessation ([@CIT0012]). It also remains possible that differences in cessation rates observed in early and late pregnancy might be explained by unmeasured factors. Furthermore, as a number of significance tests were performed, some of the observed associations may have occurred by chance (i.e., Type I errors). However, as this is the first analysis employing multivariable methods to determine factors which were independently associated with smoking cessation in a trial of NRT patches, findings remain interesting. Additionally, our study sample was large and was mostly complete, permitting inclusion of 91% of trial participants in analyses. This will have increased the likelihood that weak associations between baseline factors and validated cessation in the trial database could be discovered. A final advantage of investigating predictors in a trial of NRT is that biochemically validated cessation was used; accuracy of self-reported cessation in pregnancy is typically low due to the perceived social acceptability of smoking during pregnancy.

Findings in the Context of Previous Work {#s14}
----------------------------------------

Two previous systematic reviews, in nonpregnant ([@CIT0016]) and pregnant smokers ([@CIT0012]), respectively, have investigated predictors of smoking cessation. Both found that nicotine dependence is an important predictor of quit attempt success, with higher levels reducing the likelihood of a successful quit attempt. Our analyses provide complementary data showing, in the context of an NRT trial, that lower cotinine concentration increased the odds of cessation among trial participants in both early and late pregnancy. Cotinine levels are a marker of tobacco smoke exposure rather than being a measure of nicotine dependence. However, within these trial participants both plasma and saliva measures of cotinine have been found to be highly correlated with a validated measure of nicotine dependence in pregnancy ([@CIT0009]), so it is likely that, lower levels of nicotine dependence, would also increase the likelihood of women in this study quitting too.

The previous reviews also investigated associations between socioeconomic factors and smoking cessation and found strong evidence for a positive association between higher socioeconomic status or, higher income levels and cessation in pregnancy ([@CIT0012]); but little evidence was found for an association between income, level of education or employment status, and cessation in nonpregnant smokers ([@CIT0016]). The present study concurs with the previous findings that higher levels of social disadvantage are associated with worse outcomes in pregnant women who attempted cessation as part of an NRT trial.

In the previous review that investigated pregnant smokers' quit attempts, all included studies used self-reported cessation measures ([@CIT0012]), which may be prone to underreporting of smoking behavior due to social desirability bias and, so, the validity of findings from empirical studies included in this review could be questioned. As nonsmokers are unlikely to report themselves as smokers, misclassification of women currently smoking as nonsmokers could bias the strength of associations between factors relating to smoking behavior and addiction and those measuring social disadvantage and cessation toward the null. In our dataset, misclassification of smoking status due to such biases in self-reported data cannot have occurred; consequently, our demonstration of the importance of nicotine dependence and social disadvantage to smoking cessation is likely to be valid.

Only one previous report has used validated cessation data to investigate factors associated with successful cessation in pregnancy ([@CIT0008]). This analysis used data from the U.S. "Baby Steps" trial ([@CIT0011]) and found that women who were primiparous and who used more NRT were more likely to report cessation at 38 weeks gestation ([@CIT0008]); however, the study sample was small (104 women) and only univariable associations were reported, so these findings are difficult to interpret. Our much larger study has greater power and used a multivariable analysis, which investigated the independent associations with cessation.

The analyses presented in this paper suggest that, in pregnant women who use NRT to attempt cessation, higher levels of social disadvantage and higher pretreatment cotinine levels are associated with worse cessation outcomes. It is possible that both associations are causal, though a mechanism for cotinine concentration affecting cessation through its contribution to nicotine dependence is more immediately obvious. Outside of pregnancy, nicotine dependence is also more easily remedied, for example, by NRT, which has been shown to reduce the strength of craving and be effective ([@CIT0013]). These findings have research implications; further work investigating how socioeconomic status may influence success in quit attempts could uncover factors that are amenable to intervention. Similarly, further research into the treatment of nicotine dependence may be indicated; there is currently no evidence that NRT is effective in pregnancy ([@CIT0001]), but future studies using higher doses of nicotine than those which have been trialed could be undertaken. Nicotine metabolism is faster in pregnancy ([@CIT0005]) and the standard doses of NRT that have been investigated may be too low to be effective. The finding that increasing cotinine concentration, which is strongly correlated with nicotine dependence ([@CIT0009]), is strongly associated with cessation failure should provide a spur to investigate this possibility.

Conclusions and Recommendations {#s15}
-------------------------------

Among pregnant participants in a trial of NRT for smoking cessation, women who were not educated beyond the compulsory age for finishing school and those who had higher pretreatment cotinine concentrations were less likely to stop smoking throughout pregnancy. Women with these characteristics may require a different kind of smoking cessation support in pregnancy than others; however, it is not possible, from our data, to determine the nature of support that these women would find most helpful.
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